Medicenna - President and CEO, Fahar Merchant.
President and CEO, Fahar Merchant.
Source: The International Cytokine and Interferon Society.
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit
  • The company intends to use the funds to further develop its product pipeline
  • It expects the offering to close on or around August 11, 2022
  • Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases
  • Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share

Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit.

Each unit is comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share priced at US$1.85 for 60 months following the date of closing.

It intends to use the net proceeds to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, as well as for working capital and general corporate purposes.

Guggenheim Securities is acting as sole book-running manager with Bloom Burton Securities acting as co-manager.

The company expects the offering to close on or around August 11, 2022.

Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases, including a broad range of cancers.

Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share as of 1:48 pm EST.


More From The Market Herald

" MCI Onehealth (TSX:DRDR) clinical data insights pipeline gains momentum

MCI Onehealth (DRDR) is evolving its tech and clinical data insights through revenue deals and relationships with businesses in health and life-sciences.

" BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

BriaCell Therapeutics (BCT) presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT.

" Sokoman (TSXV:SIC) announces non-brokered flow-through private placement

Sokoman (SIC) has announced a non-brokered private placement of flow-through units for gross proceeds of up to $3,000,000.

" Sirona Biochem (TSXV:SBM) begins clinical trial for anti-aging compound TFC-1326

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.